PGNAA system preliminary design and measurement of In-Hospital Neutron Irradiator for boron concentration measurement

Zhang, Zizhu; Chong, Yizheng; Chen, Xinru; Jin, Congjun; Yang, L.; Liu, Tong

doi:10.1016/j.apradiso.2015.07.049

Cited by 14 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another category of tumors that were treated by BNCT is cutaneous melanomas. Zhang et al [130] reported the clinical treatment of cutaneous melanomas in three Chinese patients by using compact In-Hospital Neutron Irradiator (IHNI), which is specially fabricated and designed for BNCT. Out of these three patients, one has acral melanoma on the sole of his foot who had declined surgery (as indicated in Figure 10).…”

Section: Cutaneous and Genital Cancer Treatment With Bnctmentioning

confidence: 99%

Boron Chemistry for Medical Applications

2020

View full text Add to dashboard Cite

Boron compounds now have many applications in a number of fields, including Medicinal Chemistry. Although the uses of boron compounds in pharmacological science have been recognized several decades ago, surprisingly few are found in pharmaceutical drugs. The boron-containing compounds epitomize a new class for medicinal chemists to use in their drug designs. Carboranes are a class of organometallic compounds containing carbon (C), boron (B), and hydrogen (H) and are the most widely studied boron compounds in medicinal chemistry. Additionally, other boron-based compounds are of great interest, such as dodecaborate anions, metallacarboranes and metallaboranes. The boron neutron capture therapy (BNCT) has been utilized for cancer treatment from last decade, where chemotherapy and radiation have their own shortcomings. However, the improvement in the already existing (BPA and/or BSH) localized delivery agents or new tumor-targeted compounds are required before realizing the full clinical potential of BNCT. The work outlined in this short review addresses the advancements in boron containing compounds. Here, we have focused on the possible clinical implications of the new and improved boron-based biologically active compounds for BNCT that are reported to have in vivo and/or in vitro efficacy.

show abstract

Section: Cutaneous and Genital Cancer Treatment With Bnctmentioning

confidence: 99%

Boron Chemistry for Medical Applications

2020

View full text Add to dashboard Cite

show abstract

“…Based on the pioneering studies of Mishima et al [ 41 – 43 ], the third category of tumors that were discussed at the Symposium focused on melanomas, and two papers were presented. The first was by Zhang et al [ 44 ] on the treatment of three Chinese patients with cutaneous melanomas using a compact In-Hospital Neutron Irradiator (IHNI), specially designed and fabricated for BNCT [ 44 ]. One of the three was a patient with an acral melanoma on the sole of his foot who had declined surgery.…”

Section: Treatment Of Cutaneous Melanomas With Bnctmentioning

confidence: 99%

A realistic appraisal of boron neutron capture therapy as a cancer treatment modality

Barth

Zhang²,

Liu³

2018

Cancer Communications

Self Cite

171

158

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a binary therapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope boron-10 is irradiated with neutrons to produce high-energy alpha particles and recoiling lithium-7 nuclei. In this Commentary we will focus on a number of papers that were presented at a Symposium entitled “Current Clinical Status of Boron Neutron Capture Therapy and Paths to the Future”, which was held in September 2017 at the China National Convention Center in Beijing. Results were presented by clinicians from Japan, Finland, the United States, the China mainland and Taiwan, China who have been working in the multiple disciplines that are required for carrying out clinical BNCT. The main focus was on the treatment of patients with malignant brain tumors, recurrent tumors of the head and neck region, and cutaneous melanomas. The results obtained in treating these patients were reported in detail and, although most of the patients with brain tumors and head and neck cancer were not cured, there was evidence of some clinical efficacy. Although there are a number of problems that must be addressed, further clinical studies to evaluate the efficacy of BNCT are warranted. First, despite considerable effort by numerous investigators over the past 40 years, there still are only two boron-containing drugs in clinical use, l-boronophenylalanine (BPA) and sodium borocaptate (BSH). Therefore, until new and more effective boron delivery agents are developed, efforts should be directed to improving the dosing and delivery of BPA and BSH. Second, due to a variety of reasons, nuclear reactor-based BNCT has ended except for its use in the China mainland and Taiwan. Therefore, the future of BNCT depends upon the results of the ongoing Phase II clinical trials that are being carried out in Japan and the soon to be initiated trials that will be carried out in Finland. If the results obtained from these clinical trials are sufficiently promising, then BNCT will have a clear path to the future, especially for patients with the therapeutically challenging malignancies that in the past have been treated with reactor-based BNCT.

show abstract

“…In 2010, the construction of the world’s first IHNI was completed in Beijing, China (9,10). We initiated this first clinical trial to investigate whether the IHNI had sufficient potential to serve as a neutron source within a hospital for BNCT, and we report here the results of the first patient treated by an IHNI according to the protocol of BNCT.…”

Section: Introductionmentioning

confidence: 99%

Boron neutron capture therapy for malignant melanoma: first clinical case report in China

Zhong

Song

Zhou

et al. 2016

Chinese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

A phase I/II clinical trial for treating malignant melanoma by boron neutron capture therapy (BNCT) was designed to evaluate whether the world’s first in-hospital neutron irradiator (IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography (PET/CT) scan, pathological analysis and gross examination, the patient showed a complete response to BNCT, indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals.

show abstract

PGNAA system preliminary design and measurement of In-Hospital Neutron Irradiator for boron concentration measurement

Cited by 14 publications

References 1 publication

Boron Chemistry for Medical Applications

Boron Chemistry for Medical Applications

A realistic appraisal of boron neutron capture therapy as a cancer treatment modality

Boron neutron capture therapy for malignant melanoma: first clinical case report in China

Contact Info

Product

Resources

About